Kornimate/medical-research-clean huggingface dataset:
the effects of action observation therapy (aot) on balance and gait in patients with multiple sclerosis.

Conditions: Multiple Sclerosis

Summary: action observation therapy is a new method in rehabilitation that causes motor retraining by activating mirror neurons while watching the activity on the screen and then practicing them. we will use action observation therapy to improve balance and walking in ms patients.

multiple sclerosis (ms) is an inflammatory disease of the brain and spinal cord caused by damage to myelin. while the underlying cause of this disease is unknown, a significant relationship has been reported between a series of (cns) neurons of the central nervous system, immune factors, genetics, and viruses. the primary complaint of ms patients is movement problems, particularly walking disorders, which greatly affect their quality of life, and its improvement is one of the main goals of rehabilitation. action observation therapy is a new approach. it is used to treat neurological disorders such as cerebral palsy, parkinson's disease, strokes, and multiple sclerosis. in this method, a video of some purposeful movements and activities recorded by healthy people doing them is shown to the patient, then the person must try to imitate and perform those actions, which causes movement retraining and memory recall. based on the studies conducted on the effectiveness of neurological treatment methods and proving the effectiveness of this method on other conditions, also considering the involvement of the nervous system in ms and the lack of related studies, we conducted this study with regard to to design a low cost, availability, and ease of use therapeutic method on balance and walking in patients with multiple sclerosis. this study will be conducted on two groups of ms patients. after passing 30 minutes of usual rehabilitation by the blind therapist. one group will watch videos related to action observation exercises and then practice, and for the second group, a video of natural scenery will be shown for the same length of time, then they will practice exercises similar to the first group.

Eligibility criteria:
inclusion criteria: * diagnosis of spastic primary progressive, secondary progressive, relapsing-remitting ms * edss (extensive disability status scale) score between 3 and 6 * mmse (mini-mental state examination) test score\> 24 exclusion criteria: * recurrence of ms during 3 months before intervention * pregnancy and lactation * having a psychiatric disorder or drug/alcohol abuse * changes in the symptoms of ms during the study period * inability to sit without torso support * inability to stand for at least 10 seconds with support * other neurological or orthopedic diseases of the lower extremities (musculoskeletal diseases, severe osteoarthritis, peripheral neuropathy, joint replacement) * cardiovascular diseases (recent myocardial infarction, heart failure, uncontrolled hypertension, orthostatic hypotension) * participation in other clinical studies

Keywords: action observation gait balance
supervised exercise therapy vs home exercises for patients with subacromial impingement

Conditions: Shoulder Impingement Syndrome

Summary: the purpose of this study is to determine whether there are any difference between supervised exercise therapy and homebased exercise when looking at pain and function for patients with shoulder pain.

shoulder pain is common in the population. various treatment modalities are used. according to the literature, it is equally good results for home exercises and for guided exercise therapy. the purpose of this study is to look at this again and determine whether there are any difference between supervised exercise therapy and homebased exercise when looking at pain and function for patients with subacromial impingement.

Eligibility criteria:
inclusion criteria: * pain in one shoulder * had the condition for more than 12 weeks * pain at abduction (must be present in some part between 60 and 120 degrees) * pain/ weakness in isometric external rotation * positive hawkins test exclusion criteria: * instability * labral pathology * acromioclavicular joint (ac-joint) pathology * complete rupture in the rotatorcuff * glenohumeral osteoarthritis * previously operated on current shoulder * the pain comes from neck pathology * rheumatoid arthritis or other serious physical or mental illness * lack of norwegian language * unable to start

Keywords: shoulder pain shoulder impingement rotatorcuff pathology supervised exercise homebased exercise
the effect of mindfulness meditation

Conditions: Burnout; Compassion Fatigue; Psychological Well-Being

Summary: cancer is a disease that causes the most deaths worldwide and is challenging for patients and caregivers both physically and psychosocially. physicians and nurses working in oncology clinics perform a demanding profession providing compassionate care and treatment to patients struggling with life-threatening diseases. the emotional cost of caring for patients diagnosed with cancer can lead to compassion fatigue, burnout, and decreased psychological well-being among healthcare professionals. for this reason, this research is planned as a randomized controlled study to examine the effect of mindfulness meditation practice on compassion fatigue, burnout, and psychological well-being in physicians and nurses working in oncology units.


Eligibility criteria:
inclusion criteria: * actively working in oncology clinics * at least 1 year of working experience in an oncology clinic * not having a physical/mental/psychological disorder that would prevent participation in the research. * oncology nurses with a high school, undergraduate, associate or graduate degree in nursing * physicians and nurses who volunteer to participate in the research will be included in the research sample. exclusion criteria: * physicians and nurses who have been diagnosed with a psychological disease in the last two years and are continuing their medical treatment • physicians and nurses who did not agree to participate in the research

Keywords: mindfulness meditation compassion fatigue burnout psychological well-being oncology units health professionals
adherence to a recommended exercise regimen in colorectal cancer patients

Conditions: Colorectal Cancer (CRC)

Summary: given the apparent effect of 18 metabolic equivalent task-hours of activity/week in improving disease free survival in patients with treated stage 3 colon cancer and the survival benefit of exercise demonstrated in patients with stage ii and iii colorectal cancer, the primary objective is to evaluate compliance at 6 months with post-treatment recommendations for a minimum of 18 metabolic units of physical activity each week in patients who have completed therapy for stage 2 and stage 3 colorectal cancer.


Eligibility criteria:
inclusion criteria: 1. patients with histological confirmation of stage 2 or stage 3 colorectal cancer. 2. ability to sign written informed consent. 3. who performance status of 2 or better. 4. no evidence of recurrent disease or death prior to second questionnaire. 5. patients with declining physical activity within 90 days of second physical activity assessment will be excluded. there are no exclusion criteria

Keywords: treated stage 2 and stage 3 colorectal cancer
early integration of supportive care for metastatic uveal melanoma patients (earlytogether)

Conditions: Uveal Melanoma

Summary: the study main objective is to assess whether the early introduction of supportive care demonstrates a benefit on patients' psychological care needs at 6 months (m6), versus oncological standard of care in patients with metastatic um. supportive care in patients with metastatic uveal melanoma (um)

before the start of the study, medical oncologists and supportive care physicians from both the sites will attend communication skills training (cst) workshops provided by an expert team in the field. the training sessions will focus on practicing the required communication skills needed in consultations. the randomization will assign patients, with a 1:2 ratio, to "introduction of supportive care when medically needed" (arm a: control group) or "initial concomitant management by the oncologist and the supportive care team" (arm b: early together group). selected and validated questionnaires will be filled at baseline, 6 and 12 months by the patients before the consultation, in the 2 groups.

Eligibility criteria:
inclusion criteria: 1. adult patients with metastatic um; 2. no surgery or loco-regional treatment of metastases in a curative intent; 3. systemic treatment planned or started since less than 2 months; 4. ecog ps 0-1; 5. no uncontrolled symptoms; 6. liver function tests in normal range or ≤ grade 2; 7. signed informed consent; 8. able to fill the questionnaires. exclusion criteria: 1. patient\<18 years old; 2. patient condition requiring supportive care before any systemic specific treatment for metastases; 3. acute psychopathological disorder incompatible with the study; 4. prior medical condition incompatible with the study.
phase i study of lxh254 in patients with advanced solid tumors haboring mapk pathway alterations

Conditions: NSCLC; Ovarian Cancer; Melanoma; Other Solid Tumors

Summary: a phase i study of lxh254 in patients with advanced solid tumors that harbor mapk pathway alterations.


Eligibility criteria:
inclusion criteria: * all patients participating in this clinical trial must have progressed following standard therapy, or for whom, in the opinion of the investigator, no effective standard therapy exists, is tolerated or appropriate. * eastern cooperative oncology group (ecog) performance status ≤ 1 * presence of at least one measurable lesion according to recist v1.1. * documented mapk alteration additional inclusion criteria for the dose expansion part: lxh254 in combination with pdr001: * patients with confirmed kras-mutated nsclc * patients with confirmed nras-mutated melanoma (cutaneous melanoma only) exclusion criteria: - prior treatment with a brafi, meki and/or pan-raf inihibitors for patients to be enrolled in the dose expansion part. exceptions may be made after documented agreement between novartis and investigator. * history or current evidence of retinal vein occlusion (rvo) or current risk factors for rvo. * any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures. * patients receiving proton pump inhibitors which cannot be discontinued 3 days prior to the start study treatment and for the duration of the study. * pregnant or nursing (lactating) women additional exclusion criteria for lxh254 in combination with pdr001 * history of severe hypersensitivity reactions, which in the opinion of the investigator may cause in increased risk of serious infusion reaction. * known human immunodeficiency virus (hiv). * any positive test for hepatitis b virus or hepatitis c virus indicating acute or chronic infection. * active, known or suspected autoimmune disease. * active infection requiring systemic antibiotic therapy * patients requiring systemic steroid therapy or any immunosuppressive therapy (≥10mg/day prednisone or equivalent) which cannot be discontinued at least 7 days prior to first dose of study treatment. * use of any live vaccines against infectious diseases within 4 weeks of initiation of study treatment. other inclusion/exclusion criteria as per protocol may apply.

Keywords: lxh254, craf, mapk, solid tumor, pdr001
safety and effectiveness of cinnomer® (glatiramer acetate) in multiple sclerosis (ms) treatment in iran

Conditions: Relapsing Multiple Sclerosis

Summary: this trial was an obsevational phase iv prospective multicenter study designed to evaluate the safety and effectiveness of cinnomer® in patients with ms in iran. the primary objective of this study was safety assessment of cinnomer® secondary objectives were: * effectiveness assessment of cinnomer® * assessment of the patients' qol * evaluation of the patients' depression status

this trial was an observational phase iv prospective multicenter study designed to evaluate the safety and effectiveness of cinnomer® in patients with ms in iran. the primary objective of this study was safety evaluation. to evaluate the safety of cinnomer®, at each visit, the aes, seriousness of observed aes, and abnormal laboratory findings were recorded. to evaluate the effectiveness of cinnomer® as the secondary objective, the indicative parameters of ms activity, including relapse information, mri findings, and edss scores were considered. also, questionnaires assessing the patients' qol and depression were evaluated. the sample size of 368 patients and the 14 months of the study was considered applicable for safety and effectiveness evaluation of cinnomer®, 40 mg/ml, three times per week, in patients with relapsing forms of ms.

Eligibility criteria:
inclusion criteria: * patients with rrms * patients diagnosed as spms with relapse * all the patients taking other dmts and their medication had been changed to cinnomer® due to any reason. * 0 ≤ edss ≤ 5 * 18 ≤ age ≤ 60 exclusion criteria: * history of hypersensitivity to glatiramer acetate, mannitol, or any component of the formulation. * in the investigator's opinion, any reason that makes the subject unsuitable for treatment with cinnomer®.

Keywords: glatiramer acetate multiple sclerosis quality of life cinnomer annualized relapse rate safety relapsing
adapting the facets program to sickle cell disease

Conditions: Fatigue Symptom; Sickle Cell Disease

Summary: adaptation of a fatigue management program combining the principles of cognitive-behavioral therapy and energy conservation strategies (facets program) for a population of adult patients with sickle cell disease (drépa-facets program).


Eligibility criteria:
inclusion criteria: * participant having freely given his oral agreement. * participant with a major sickle cell syndrome, regardless of genotype (e.g. ss, sc, sbeta). * participant with a sufficient command of spoken and written french to take the assessments, complete the questionnaires, follow the program sessions and carry out the home exercises. exclusion criteria: * participant with one or more severe psychiatric pathologies (e.g. severe depression, psychosis) that could interfere with the conduct of the study, in particular the primary and secondary endpoints. * participants with another chronic pathology causing fatigue. * participants in vaso-occlusive crisis (voc) or hospitalization. * participant under legal protection (guardianship, curatorship, safeguard of justice, deprived of liberty).
cic behavioral economics in children with spina bifida

Conditions: Spina Bifida; Neurogenic Bladder

Summary: the purpose of the study is to develop a comprehensive program to increase early initiation of self-catheterization in children with spina bifida. this will be a prospective open label randomized control trial. patients and caregivers/guardians in the intervention arm will be enrolled in a comprehensive program that utilizes behavioral economic theory to incentivize initiation of independent cic. the study population will be patients aged 4 to 12 years old with diagnosis of spina bifida, including meningocele and myelomeningocele, as defined by international classification of diseases, 10th revision (icd10). this study will look at behavioral interventions. there are no additional physical risks to participation in the study. patient demographics will be reported using descriptive statistics. study team will use kaplan-meier curves to demonstrate and compare the probability of achieving independent cic over time between the study arms.

there are three study arms to which patients will be randomized in block randomization fashion with goal recruitment totaling 45 patients. randomization will begin with arm 1 and arm 2 in a 1:1 ratio for the first 20 patients, 10 patients per arm. if accrual is reasonably brisk, we will expand our recruitment to arm 3 which will then be conducted in a 1:1:3 block randomization for the remaining 25 patients with a total of 15 patients per arm. if accrual is slow and recruitment goal will not be met by expected date, we will continue accrual to arm 1 and arm 2 without including arm 3. randomization will be performed via nih clinical trial randomization tool.

Eligibility criteria:
inclusion criteria: * diagnosis of spina bifida, including meningocele and myelomeningocele, as defined by international classification of diseases, 10th revision (icd10). icd-10 codes will include q05.0-q05.9 * 4-12 years old * cic performed fully by their caregiver * demonstrate manual dexterity to perform cic (determined by the patient's caregiver and the pediatric urologist in clinic) * communication in english language exclusion criteria: * non-english speaking patients * less than 4 years old; older than 12 years of age * non-spina bifida patients * already perform independent or semi-independent cic

Keywords: clean intermittent catheterization spina bifida neurogenic bladder behavioral economics
gender-responsive treatment for women offenders - 1

Conditions: Substance Abuse Problem

Summary: the purpose of this study is to determine whether substance abuse treatment designed specifically for drug-dependent women offenders provides better outcomes than standard drug court treatment (mixed-gender programs).

in this five-year study, a total of 300 women entering court-referred treatment throughout los angeles county and who agree to participate in the study will be randomly assigned to a women-focused or to a mixed-gender outpatient treatment program. the study will assess the impact of women-focused substance abuse treatment using outcome measures including recidivism, substance abuse and relapse, and social adjustment (e.g., employment, parenting behaviors, psychological improvement, and hiv risk reduction behaviors), compared to the impact of traditional mixed-gender programs. assessments will occur at baseline and at 1 month, 12 months, and 24 months after admission.

Eligibility criteria:
inclusion criteria: * drug court participant * at least eighteen (18) years old * have had no more than three prior non-violent, non-drug felony convictions * do not have a current charge of driving under the influence of alcohol or drugs or a charge of sale or transportation of drugs exclusion criteria: * not capable of giving informed consent

Keywords: gender-responsive substance abuse treatment
efficacy and safety of levosimendan in severe acute heart failure in critical children

Conditions: Acute Heart Failure

Summary: to evaluate the efficacy and safety of levosimendan versus conventional intensified inotropic treatment, in critical children with severe acute heart failure which persists despite of having received conventional inotropic treatment.


Eligibility criteria:
inclusion criteria: * patients who give written consent to participate in the study and for the transfer of material for cellular and molecular studies. * understand the purpose of the study and to be available to perform the procedures written in the protocol. * any child of 1 day old to 18 years old, admitted to the paediatric intensive care unit due to severe acute heart failure of any etiology. exclusion criteria: all patients who * express their wish of not to participate in the protocol * have hypertrophic or restrictive cardiomyopathy * have aortic stenosis * have a known allergy to any drug used in the study * it is not possible to prescribe the study medication because it is contraindicated according to the summary of the product characteristic or according to the criteria of the physician responsible for patient * are pregnant

Keywords: acute heart failure children levosimendan inotropic treatment
therapeutic effects analysis of pudendal nerve infiltrations after 3 months, in patients suffering of pudendal neuralgia

Conditions: Pudendal Neuralgia; Canal Syndrome

Summary: pudendal neuralgia is a recent identified pathology, extremely invalidating, related to chronic pelvic entrapment. nowadays, pudendal neuralgia can be treated with: * neuropathic pains treatment * specific kinesitherapy * alcock's canal and sacrospinal ligament infiltrations under scan * with diagnostic block * local steroids injections * and surgical decompression of pudendal nerve with transrectal approach. only surgery was validated after a randomised protocol studying surgery versus abstention, performed and published by the chu de nantes. many techniques have been proposed for realization of pudendal nerve infiltrations. the results of these infiltrations have never been published, and no randomised study had ever evaluated those results, even at short-run. very few randomized studies have validated steroids infiltrations techniques in canal syndrome neuropathies. the primary objective of the investigators phase iv trial is to evaluate the efficacy of three different types of pudendal nerve infiltrations in alcock's canal and sacrospinal ligament: * group a: only local anesthetic (control arm) * group b: local anesthetics associated with local steroids * group c: local anesthetics associated with local steroids and important volumes of physiological serum


Eligibility criteria:
inclusion criteria: * patient presenting the four indispensable clinical criteria for pudendal neuralgia (nantes' criteria) * man or woman aged more than 18 years old * suffering from pudendal neuralgia since more than six months * without previous infiltration identical to the one proposed by the protocol * without previous surgery of pudendal nerve * without any hemorrhagic risk factor * no contra-indication to lidocaïne, depo-medrol or contrast-product injections * pain intensity with an average \> or = 40/100 (measured by scales during the fifteen days before infiltration) exclusion criteria: * patient presenting one of the four exclusion clinical criterium for pudendal neuralgia (nantes' criteria) * patient who has filled his "pain note book" during less than 5 days over the 15 days before the infiltration * pregnancy * depression (beck scale \> 16/39)

Keywords: pudendal neuralgia pudendal nerve alcock's canal syndrome canal syndrome neuropathic pain infiltration randomized protocol pain scales